1. Academic Validation
  2. Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis

Inhibition of Rho-dependent kinases ROCK I/II activates VEGF-driven retinal neovascularization and sprouting angiogenesis

  • Am J Physiol Heart Circ Physiol. 2009 Mar;296(3):H893-9. doi: 10.1152/ajpheart.01038.2008.
Jens Kroll 1 Daniel Epting Katrin Kern Christian T Dietz Yuxi Feng Hans-Peter Hammes Thomas Wieland Hellmut G Augustin
Affiliations

Affiliation

  • 1 Center for Biomedicine and Medical Technology Mannheim, Joint Research Division Vascular Biology Medical Faculty Mannheim, Univ. of Heidelberg and the German Cancer Research Center, Ludolf-Krehl-Str. 13-17, 68167 Mannheim, Germany. [email protected]
Abstract

Vascular endothelial growth factor (VEGF) is an endothelial-specific growth factor that activates the small GTPase RhoA. While the role of RhoA for VEGF-driven endothelial migration and angiogenesis has been studied in detail, the function of its target proteins, the Rho-dependent kinases ROCK I and II, are controversially discussed. Using the mouse model of oxygen-induced proliferative retinopathy, ROCK I/II inhibition by H-1152 resulted in increased angiogenesis. This enhanced angiogenesis, however, was completely blocked by the VEGF-receptor antagonist PTK787/ZK222584. Loss-of-function experiments in endothelial cells revealed that inhibition of ROCK I/II using the pharmacological inhibitor H-1152 and ROCK I/II-specific small-interfering RNAs resulted in a rise of VEGF-driven sprouting angiogenesis. These functional data were biochemically substantiated by showing an enhanced VEGF-receptor kinase insert domain receptor phosphorylation and extracellular signal-regulated kinase 1/2 activation after inhibition of ROCK I/II. Thus our data identify that the inhibition of Rho-dependent kinases ROCK I/II activates angiogenesis both, in vitro and in vivo.

Figures